Galena Biopharma Inc. Blog | Talkmarkets | Page 2
No data available
No data available

People who follow this stock (46)

Latest Posts

About This Stock More About This Stock
Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update
Article By: The Life Sciences Report
Wednesday, March 9, 2016 5:47 PM EDT
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.
In this article: SGYP, CRMD, ORMP, SRNE, ARRY, PTIE, AGEN, GALE, PPHM, EVOK, ADMA, AKBA, KPTI, VSTM, AST, RXDX, AGTC, WVE, FATE, FLKS, PIRS, ABEO
Read
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
Article By: The Life Sciences Report
Wednesday, January 27, 2016 6:16 PM EDT
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS
Read
E Galena Biopharma Announces Reduction Of Cardiac Toxicity Study For Neuvax Trial
Article By: Terry Chrisomalis
Monday, August 24, 2015 6:39 PM EDT
Shares of Galena Biopharma (GALE) closed the day up 11%, after announcing reduction of cardiac toxicity study for Neuvax trial.
In this article: GALE
Read
E Galena Biopharma Launches Anti-Nausea Drug Zuplenz
Article By: Terry Chrisomalis
Wednesday, July 29, 2015 2:31 PM EDT
Galena Biopharma shares are up 5% after announcing the launch of an anti-nausea drug known as Zuplenz, indicated for use in post-chemo, post-radiation and post-surgical patients.
In this article: GALE
Read
Gilead’s Hep C Drug Receives Approval In Japan - Analyst Reactions
Article By: TipRanks
Tuesday, March 31, 2015 10:58 AM EDT
Sovaldi becomes the first Gilead drug available in Japan. Overall analyst consensus is Strong Buy.
In this article: GILD, MDVN, GALE
Read

Latest Tweets for $GALE

No tweets yet!